key: cord-1000430-zvmv1up2
authors: Silvestre, Odilson M; Costa, Letícia R; Lopes, Bianca V R; Barbosa, Mariana R; Botelho, Kárenn K P; Albuquerque, Kelvyn L C; Souza, Anna G S; Coelho, Lorran A; de Oliveira, Anderson J; Barantini, Cínthia B; Neves, Sebastião A V M; Nadruz, Wilson; Maguire, James H; Fernandes-Silva, Miguel M
title: Previous dengue infection and mortality in COVID-19
date: 2020-12-29
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1895
sha: 54a8ef6ddfb014c73afbc099eed2219baaee7e2b
doc_id: 1000430
cord_uid: zvmv1up2

We studied 2351 participants with COVID-19, 1177 (50%) reported previous dengue infection. Those without previous dengue had a higher risk of death (hazard ratio: 0.44; 95% CI: 0.22 to 0.89; p = 0.023) in 60-day follow-up. These findings raise the possibility that dengue might induce immunological protection against SARS COV-2.

COVID-19 is a pandemic infectious disease notable for high infectivity and potential severity. It can evolve to respiratory distress, the main cause of COVID-19 hospitalization and death [1, 2] . The mechanisms for disease severity are likely related to viral load and the host's inflammatory response; common chronic diseases such as diabetes, hypertension and cardiovascular diseases are associated with a poor prognosis [3] . In the absence of an approved effective vaccine, protective factors that increase survival among those infected with SARS COV-2 are of interest to investigators.

Data recently published from an ecological study in Brazil, other Latin American countries, and Asia showed that areas with a higher incidence of dengue fever were less likely to experience COVID-19 cases and deaths [4] , raising the possibility of cross-immunity between these two viruses. Indeed, although dengue virus and SARS-COV-2 are from different families, there are reports that antibodies for dengue can be reactive against SARS COV-2, leading to false positive tests for COVID-19 [5, 6] . However, it is unknown whether previous dengue episodes can produce some level of immunity against COVID-19. Our aim was to evaluate whether previous contact with endemic infectious diseases such as symptomatic dengue might alter the prognosis of COVID-19.

We prospectively studied 2830 subjects with symptomatic and asymptomatic laboratory-confirmed SARS-CoV-2 infection in Rio Branco, Acre, a municipality in the Brazilian Amazon basin. From the 9,878 cases of COVID-19 registered in the health 

Sociodemographic information, clinical data prior to SARS-CoV-2 infection, and COVID-19 specific clinical information were collected. Data provided by telephone from the patient or the patient's family member included: weight, height, skin color, education level, monthly income, active smoking, relevant comorbidities for severe COVID-19 (hypertension, diabetes, heart disease, pulmonary disease and chronic kidney disease), history of symptomatic dengue, and history of other endemic infectious diseases (malaria, zika, chikungunya, leprosy, and visceral leishmaniasis). Symptoms related to COVID-19 infection, self-reported peripheral capillary oxygen saturation values (SpO 2 ), date of onset of symptoms, and date of resolution of symptoms were recorded. Additionally, data on medications, need for hospitalization, and survival status were ascertained by telephone call to patients or family. The first day of follow-up was defined as onset of A c c e p t e d M a n u s c r i p t symptoms, and the primary outcome was all-cause mortality up to 60 days after symptom onset.

Continuous variables with normal and non-normal distribution and categorical variables were expressed as mean ± standard deviation, median [25 th -75 th percentile] and percentages, and were compared by student-t, Mann-Whitney, and chi-square tests, respectively. The Kaplan-Meier method estimated the cumulative event rate, and comparisons between curves were made by log-rank test. Multivariable Cox proportional hazards regression models to evaluate the association between symptomatic dengue and mortality were adjusted for selected covariates based on prior literature (age, sex, number of relevant comorbidities [obesity, hypertension, diabetes, heart disease, pulmonary disease and chronic kidney disease], hospitalization, SpO2<95%, and treatment with corticosteroids).

Because the main aim of this study was to evaluate the association between dengue and mortality, no adjustment for multiple comparisons was performed. Stata 15.1 was used for statistical analysis.

The value of p < 0.05 was considered statistically significant. 

The main finding of the present study was a decreased mortality at up to 60 days among COVID-19 patients who had a previous history of symptomatic dengue infection.

Participants were included from the community and had a case-fatality rate of 1.6%, similar to previously published data [1] . In a recent ecological study, the spread of COVID-19 was linked to the distribution of dengue cases in Brazil and Asia [4] . Notably, regions with higher incidence of dengue had lower number of COVID-19 cases and lower COVID-19 related mortality. These findings raise the possibility that dengue might induce a degree of immunological protection against SARS COV-2 infection. In agreement with this assumption, false-positive results for COVID-19 tests have been reported in patients with dengue [5, 6] , and false-positive IgM/IgG serological tests for SARS-CoV-2 have been reported in samples of persons with antibody-positive dengue collected in the pre-pandemic period [5, 7] . Furthermore, two patients in Singapore with thrombocytopenia, myalgia and nonspecific symptoms suggestive of dengue had false-positive tests for dengue and were later A c c e p t e d M a n u s c r i p t diagnosed with COVID-19 [6] . Overall, these reports suggest cross-immunity between the two diseases.

Symptoms of COVID-19 were more prominent among persons who had a history of dengue despite their lower mortality. This might be due to an enhanced inflammatory response, perhaps similar to the severe symptoms associated with a second episode of dengue or severe primary dengue in previously uninfected persons who received the tetravalent dengue vaccine Dengvaxia® [8] . Whether deleterious effects from immune enhancement will occur in COVID-19 reinfection or after COVID-19 vaccination remains to be determined.

This study has limitations. We cannot exclude information bias, since all data were collected directly from patients or in 3.8% of cases, their families. Dengue was self-reported, and participants may have been incorrectly classified as having or not previous history of dengue infection. We performed a sensitivity analysis for nondifferential misclassification of the exposure with probability density functions of sensitivities and specificities ranging from 0.70 to 1. We found that the bias-adjusted incidence rate ratios were further from the null (0.26; 95% CI: 0.08 to 0.63), suggesting that it is unlikely the inverse association between dengue and mortality resulted from misclassification bias. Recall bias is possible since participants who reported previous dengue infection may have been more likely to recall comorbidities than those without dengue infection. Additionally, those without dengue infection may have been less likely to receive treatment for chronic conditions, such as hypertension; however, we did not find differences in antihypertensive medications use between those with or without previous dengue (Supplementary Table 3 )." Although we adjusted for covariates known to be associated with mortality from COVID-19, we cannot rule out our results were due to unrecognized or residual confounding. Finally, our findings cannot be generalized to indigenous persons, since none of the participants self-declared as belonging to this population.

Our study suggests that individuals with history of dengue infection have lower mortality from COVID-19. Nevertheless, we cannot assume a causal association between previous dengue and immunity improving prognosis from SARS-COV2 infection. Further studies comparing previous

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a reuport of 72 314 cases from the Chinese Center for Disease Control and Prevention

China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China

A chronicle of SARS-CoV-2: Part-I -Epidemiology, diagnosis, prognosis, transmission, and treatment. Science of The Total Environment

How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil. medRxiv

Dengue Antibodies Can Cross-React with SARS-CoV-2 and Vice Versa-Antibody Detection Kits Can Give False-Positive Results for Both Viruses in Regions Where Both COVID19 and Dengue Co-Exist

Covert COVID-19 and false-positive dengue serology in Singapore

Potential antigenic crossreactivity between SARS-CoV-2 and Dengue viruses

A review of Dengvaxia®: development to deployment

Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective

Co-infection of SARS-CoV-2 and dengue virus: a clinical challenge

Dengue in the Amazon: epidemiological aspects in Rondônia State, Brazil

Secretaria de Vigilância em Saúde

Nº 31

The authors thank the Federal University of Acre for its important contribution with student scholarships.

The authors report no conflicts of interest.

M a n u s c r i p t exposure to dengue virus and the different outcomes of COVID-19 are necessary to elucidate the association between these two viruses. [9, 10] This is of particular importance to Brazil, which accounted for 70% of all dengue cases in the Americas during the last three decades. [11, 12] Whether other tropical diseases can alter the course of COVID-19 is of relevance to the greater than one billion persons living in areas where these diseases are endemic. Forest plot displays the respective hazard ratios (HR) and 95% confidence intervals (95%CI) in the multivariate Cox regression analysis.SpO2 -peripheral capillary oxygen saturation; "no hypoxemia" includes persons who did not have SpO2 measured.*Represents the HR (95%CI) for each additional comorbidity (obesity, hypertension, diabetes, heart disease, pulmonary disease or chronic kidney disease). Participants with missing body mass index (n=37) were considered non obese.A c c e p t e d M a n u s c r i p t